United States· US:55513-509_1b60403e-86c5-4694-8cb5-2fc19f46dc49
Evenity
A romosozumab product containing romosozumab, registered in United States by Amgen, Inc. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Romosozumab is registered in 15 of 19 countries.
Countries holding a registration under ATC M05BX06 (romosozumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Romosozumab · ATC M05BX06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of romosozumab costs, country by country.
Normalised to the WHO defined daily dose (7 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Romosozumab · price per daily dose (7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$19.87
- ES Spain$17.72
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ROMOSOZUMAB
- Manufacturer
- Amgen, Inc
- Country
- United States (US)
- ATC code
- M05BX06
- ATC class
- Romosozumab
- Defined daily dose
- 7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1155513-509-02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
53 interactions on record for romosozumab.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Romosozumab · interactions on record
53 records
- 1 severe
- 52 moderate
Most severe, free to view
- EtelcalcetideH05BX04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Romosozumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEVENITYUCB Pharma SA, Brusel
- IrelandEVENITY 105 mg solution for injection in pre-filled penUCB Pharma S.A.
- FinlandEVENITYUCB Pharma SA
- BelgiumEvenity 105 mgUCB Pharma
- IcelandEvenityUCB Pharma S.A.*
- NetherlandsEvenity 105 mg oplossing voor injectie in een voorgevulde penUCB Pharma S.A.
- PolandEvenityUCB Pharma S.A.
- SwedenEVENITY 105 mg Injektionsvätska, lösning i förfylld injektionspennaUCB Pharma S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Evenity
- Liechtenstein · Evenity
- Norway · Evenity
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d29e4acd-21de-44ed-9d58-e409b0fd5721 GET /v1/drugs/d29e4acd-21de-44ed-9d58-e409b0fd5721?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "105",
"substance": "ROMOSOZUMAB",
"productndc": "55513-509",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1.17mL",
"application_number": "BLA761062",
"marketing_category": "BLA"
}See everything about romosozumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.